Bavarian Nordic initiates phase II trial for Covid-19 vaccine
In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL TF
After having recently published promising data for its ABNCoV2 vaccine against Covid-19, Bavarian Nordic now begins a phase II trial for its candidate, Bavarian informs in a press release Monday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
